Potential emergence of terbinafine resistance by squalene epoxidase gene mutations: An 18‐month cohort study of onychomycosis patients in the United States
Mycoses · 2024-07 · 67 (7)
DOI: 10.1111/myc.13768 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Mycoses, online erschienen am 22.07.2024. Verfasst von Aditya K Gupta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Onychomycosis, Squalene Monooxygenase, Terbinafine, Drug Resistance, Fungal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
There is a concerning rise in antifungal‐resistant dermatophytosis globally, with resistance to terbinafine conferred by point mutations in the squalene epoxidase ( SQLE ) gene.
Objectives
Report changes in the prevalence and profile of SQLE mutations in onychomycosis patients in the United States.
Methods
A longitudinal cohort study of toenail samples was collected from suspected onychomycosis patients over an 18‐month period from 2022 to 2023. Samples were submitted from across the United States and subjected to multiplex real‐time polymerase chain reactions for dermatophyte detection, with further screening of SQLE mutations at four known hotspots (393 Leu , 397 Phe , 415 Phe and 440 His ).
Results
A total of 62,056 samples were submitted (mean age: 57.5 years; female: 60.4%). Dermatophytes were detected in 38.5% of samples, primarily Trichophyton rubrum complex (83.6%) and T. mentagrophytes complex (10.7%). A survey of SQLE mutations was carried out in 22,610 dermatophyte samples; there was a significant increase in the prevalence of SQLE mutations between the first quarter of 2022 and the second quarter of 2023 (29.0 to 61.9 per 1000 persons). The Phe397Leu substitution was the predominant mutation; Phe415Ser and His440Tyr have also emerged which were previously reported as minor mutations in skin samples. The temporal change in mutation rates can be primarily attributed to the Phe415Ser substitution. Samples from elderly patients (>70 years) are more likely to be infected with the T. mentagrophytes complex including strains harbouring the Phe415Ser substitution.
Conclusion
The prevalence of SQLE mutations among onychomycosis patients with Trichophyton infections may be underestimated. Older individuals may have a higher risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Mediprobe Research Inc., London, Ontario, Canada.
- Bako Diagnostics, Alpharetta, Georgia, USA.
- Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
ORCID-Profile: Aditya K Gupta
Zitieren
APA
Gupta, A. K., Wang, T., Polla Ravi, S., Cooper, E. A., Bamimore, M. A., Lincoln, S. A., Foreman, H. C., Piguet, V., & Bakotic, W. L. (2024). Potential emergence of terbinafine resistance by squalene epoxidase gene mutations: An 18‐month cohort study of onychomycosis patients in the United States. Mycoses, 67(7). https://doi.org/10.1111/myc.13768
Vancouver
Gupta AK, Wang T, Polla Ravi S, Cooper EA, Bamimore MA, Lincoln SA, et al. Potential emergence of terbinafine resistance by squalene epoxidase gene mutations: An 18‐month cohort study of onychomycosis patients in the United States. Mycoses. 2024;67(7). doi:10.1111/myc.13768
BibTeX
@article{Gupta2024,
author = {Gupta, Aditya K and Wang, Tong and Polla Ravi, Shruthi and Cooper, Elizabeth A and Bamimore, Mary A and Lincoln, Sara A and Foreman, Hui-Chen and Piguet, Vincent and Bakotic, Wayne L},
title = {Potential emergence of terbinafine resistance by squalene epoxidase gene mutations: An 18‐month cohort study of onychomycosis patients in the United States},
journal = {Mycoses},
year = {2024},
volume = {67},
number = {7},
doi = {10.1111/myc.13768}
}
EUVIMED